Table 3 summarizes the predictors of peripheral neuropathy (at various frequencies), red blood cell parameters (Hgb and Htc), and abnormal albuminuria (MAU) at baseline (Week 0), prior to the initiation of SGLT-2 inhibitor therapy. Here, SLC5A2 is linked to peripheral neuropathy.